Invesco Ltd. raised its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,986,272 shares of the company's stock after purchasing an additional 1,961,051 shares during the quarter. Invesco Ltd. owned about 0.89% of Kenvue worth $362,657,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the business. Grove Bank & Trust raised its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. raised its stake in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares in the last quarter. Fortitude Family Office LLC lifted its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc boosted its stake in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Trading Up 0.6 %
NYSE KVUE traded up $0.14 during trading hours on Tuesday, hitting $22.85. 5,209,527 shares of the company's stock were exchanged, compared to its average volume of 16,872,270. The business's 50 day moving average is $22.69 and its 200-day moving average is $22.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market capitalization of $43.67 billion, a P/E ratio of 43.11, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. Kenvue's dividend payout ratio is presently 154.72%.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $24.42.
Check Out Our Latest Analysis on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
